Background: Syndecans includes a group of proteins from the cell-surface heparan-sulfate proteoglycan family, with a relevant role in chronic inflammation of synovial tissue in patients with rheumatoid arthritis (RA) participating in the cell-matrix and cell-cell interactions. Syndecans are differentially expressed in the synovial tissue: syndecan-1 (SDC-1) is expressed mainly in mononuclear cells, syndecan-3 (SDC-3) is mainly expressed by synovial endothelial cells and syndecan-4 (SDC-4) is expressed by B lymphocytes regulating B cell development and survival. Currently, there is strong evidence that antibodies directed to citrullinated protein antigens (ACPAs) are associated with a more severe disease in RA. Nevertheless, to date, there is a lack of information about the relation between serum syndecan levels and serum concentrations of rheumatoid factor (RF) and ACPAs. Objectives: To evaluate the association between serum SDC-1, SDC-3 and SDC-4 levels with serum concentrations of RF and ACPAs. Methods: Eighty-one, patients with RA were included. We assessed clinical characteristics including disease activity by DAS-28, functioning by HAQ-Di. Serum concentrations of RF were measured by nephelometry, two ACPAs were measured: anti-CCP2 and anti-mutated citrullinated vimentin (anti-MCV) antibodies using ELISA. Serum levels of SDC-1, SDC-3 (ng/mL) and SDC-4 (pg/mL) were measured by ELISA. We compared the serum levels of these syndecans in the ACPA+ group (group 1) versus ACPA-group (group 2) with Student t-test. A correlation analysis (Pearson tests) was performed to identify the strength of association between concentrations of syndecans with concentrations of ACPAs and other variables. Results: Patients with RA had a mean age of 50±11 yrs, 75% were RF+ and 64% were ACPA+. In patients with ACPAs+ were observed higher serum concentrations of SDC-3 (p=0.003) and SDC-4 (p<0.001). SDC-1 correlated significantly with anti-MCV (r=0.53, p<0.001). Serum concentrations of SDC-3 correlated significantly with anti-CCP titres (r=0.53, p=0.003) and anti-MCV (r=0.46, p=0.02); whereas SDC-4 levels correlated significantly with anti-CCP titres (r=0.61, p<0.001) and RF (r=0.53, p=0.003). Additionally, serum SDC-1 levels correlated with decrement in response to treatment with synthetic DMARDs (r=-0.25, p=0.026). SDC-1 did not correlate with serum SDC-3 (p=0.8) and 
THU0162 RELATIONSHIP BETWEEN LEVELS OF HUMAN PEPTIDYL ARGININE DEIMINASE-4 WITH CHRONIC PERIODONTITIS SEVERE IN RHEUMATOID ARTHRITIS
Background: Both Peptydil arginine deiminase of P. gingivalis (pPAD), and the human enzyme (hPAD), could citrullinarize peptides from the bacteria and human host in Rheumatoid Arthritis patients (RA). Chronic periodontitis (CP) could be associated with a constant generation of citrullinated proteins, and it lead to a proportional hPAD enzymatic production.
Objectives:
The aim was to demonstrate the association between serum levels of hPAD4 and severe Periodontitis in patients with rheumatoid arthritis. Methods: Patients with RA (n=127) matched with healthy controls (n=120) were studied in a cross-sectional study. Levels of human recombinant antigens for hPAD4; cyclic citrullinated peptide antibody (CCP3, IgG), Rheumatoid factor (IgM) and C-reactive protein (CRP); determined by ELISA test. The CP was classified according to the recommendations of the International Workshop for Classification of Periodontal Diseases and Conditions. Bivariate analysis to demonstrate the associations, and non-parametric analyzes were used according to the case. Results: There were no significant demographic diffrences between the two groups. The median hPAD4 level was 1.21 (95% CI 1.4-1.7) in RA and 0.75 (95% CI 0.94-1.26) ng/ml in controls, (p<0.004). The median hPAD4 level in patients with RA and CP was 1.32 (95% CI 1.39-1.9) Vs control with CP 0.7 (95% CI 0.94-1.5) ng/ml, p<0.04. The frequency of CP was higher in patients with RA than in controls (66.9 vs 43%, p<0.000; OR: 2.65 (95% CI: 1.58-4.44); these values showed a low correlation (0.24). The median level of hPAD4 was associated with CP extension, p<0.000 and severity, p<0.000. A significant correlation was found between levels of hPAD4 with the DAS28 ESR score (p<0.002). The high score of HAQ-DI (>2.0) correlated with hPAD4 levels (P<0.001). The group of people with higher HAQ-DI score and at the same time with greater severity of CP (n=12) showed increased levels PAD4 (p<0.025). Conclusions: hPAD4 levels correlate with the severity of CP independent of the RA presence and in RA subjects with high score of disability and activity disease. The hPAD4 could be proposed as a serological marker of clinical severity in chronic diseases such as CP and RA. 
